Journal Article

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Geyer, Charles E, Pisansky, Thomas M, Bryant, John, Mamounas, Eleftherios P, Perez, Edith A, Kaufman, Peter A, Lingle, Wilma L, Tan-Chiu, Elizabeth, Klein, Pamela M, Jenkins, Robert B, Davidson, Nancy E, Brown, Ann M, Ingle, James N, Vogel, Victor G, Paik, Soonmyung, Yothers, Greg, Fehrenbacher, Louis, Swain, Sandra M, Kutteh, Leila A, Martino, Silvana, Suman, Vera J, Visscher, Daniel W, Dakhil, Shaker R, Romond, Edward H, Wolmark, Norman

2005

Overview

A combined analysis of two large studies found that the addition of trastuzumab to chemotherapy with doxorubicin and cyclophosphamide plus paclitaxel improved the outcome among women with operable HER2-positive breast cancer. An analysis of two large studies found that the addition of trastuzumab to chemotherapy with doxorubicin and cyclophosphamide plus paclitaxel improved the outcome among women with operable HER2-positive breast cancer. Trastuzumab, a monoclonal antibody targeting the extracellular domain of the HER2 protein, was approved in 1998 as a first-line treatment in combination with paclitaxel for HER2-positive metastatic breast cancer. 1 The benefit of this approach in patients with metastatic disease and the poor prognosis of HER2-positive breast cancer 2 , 3 motivated the National Cancer Institute (NCI) to sponsor two trials of adjuvant treatment with trastuzumab, led by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG). NSABP trial B-31, which began accrual in February 2000, compares four cycles of doxorubicin and cyclophosphamide followed by . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal - therapeutic use / Antibodies, Monoclonal, Humanized / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biological and medical sciences / Breast cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - mortality / Breast Neoplasms - radiotherapy / Breast Neoplasms - surgery / Cancer therapies / Chemotherapy, Adjuvant / Cyclophosphamide - administration & dosage / Disease-Free Survival / Doxorubicin - administration & dosage / Doxorubicin - analogs & derivatives / FDA approval / Female / General aspects / Gynecology. Andrology. Obstetrics / Heart Diseases - chemically induced / Humans / Mammary gland diseases / Mastectomy / Medical sciences / Middle Aged / Paclitaxel - administration & dosage / Proportional Hazards Models / Radiation therapy / Receptor, ErbB-2 - analysis / Recurrence / Survival Analysis / Trastuzumab / Tumors